- Home
- VATE vs BLRX Comparison
VATE vs BLRX Comparison
Compare VATE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VATE
- BLRX
- Stock Information
- Founded
- VATE 1994
- BLRX 2003
- Country
- VATE United States
- BLRX Israel
- Employees
- VATE N/A
- BLRX N/A
- Industry
- VATE Metal Fabrications
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- VATE Industrials
- BLRX Health Care
- Exchange
- VATE Nasdaq
- BLRX Nasdaq
- Market Cap
- VATE 49.2M
- BLRX 54.1M
- IPO Year
- VATE 1996
- BLRX 2011
- Fundamental
- Price
- VATE $3.47
- BLRX $0.46
- Analyst Decision
- VATE
- BLRX Strong Buy
- Analyst Count
- VATE 0
- BLRX 2
- Target Price
- VATE N/A
- BLRX $11.50
- AVG Volume (30 Days)
- VATE 90.6K
- BLRX 202.4K
- Earning Date
- VATE 11-07-2024
- BLRX 11-18-2024
- Dividend Yield
- VATE N/A
- BLRX N/A
- EPS Growth
- VATE N/A
- BLRX N/A
- EPS
- VATE N/A
- BLRX N/A
- Revenue
- VATE $1,364,600,000.00
- BLRX $17,048,000.00
- Revenue This Year
- VATE N/A
- BLRX N/A
- Revenue Next Year
- VATE N/A
- BLRX N/A
- P/E Ratio
- VATE N/A
- BLRX N/A
- Revenue Growth
- VATE N/A
- BLRX N/A
- 52 Week Low
- VATE $3.25
- BLRX $0.44
- 52 Week High
- VATE $15.60
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- VATE 37.74
- BLRX 23.64
- Support Level
- VATE $3.25
- BLRX $0.50
- Resistance Level
- VATE $4.16
- BLRX $0.56
- Average True Range (ATR)
- VATE 0.23
- BLRX 0.05
- MACD
- VATE -0.02
- BLRX -0.01
- Stochastic Oscillator
- VATE 22.87
- BLRX 10.60
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting stations across the United States.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.